Recent ZNTL News
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2024 09:30:00 PM
- Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 • GlobeNewswire Inc. • 04/02/2024 08:05:00 PM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/01/2024 09:30:00 PM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 11:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/29/2024 10:20:16 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/29/2024 10:14:29 PM
- Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:08:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:04:11 PM
- Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:12:34 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:43:38 AM
- Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 01:25:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 01:25:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 01:22:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:15:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:14:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:12:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:11:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2024 02:29:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2024 02:29:15 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2024 02:28:51 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2024 02:27:33 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2024 02:26:57 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM